143 related articles for article (PubMed ID: 12113833)
1. 4-Aminoarylguanidine and 4-aminobenzamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors.
Spencer JR; McGee D; Allen D; Katz BA; Luong C; Sendzik M; Squires N; Mackman RL
Bioorg Med Chem Lett; 2002 Aug; 12(15):2023-6. PubMed ID: 12113833
[TBL] [Abstract][Full Text] [Related]
2. 2-(2-Hydroxy-3-alkoxyphenyl)-1H-benzimidazole-5-carboxamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors.
Mackman RL; Hui HC; Breitenbucher JG; Katz BA; Luong C; Martelli A; McGee D; Radika K; Sendzik M; Spencer JR; Sprengeler PA; Tario J; Verner E; Wang J
Bioorg Med Chem Lett; 2002 Aug; 12(15):2019-22. PubMed ID: 12113832
[TBL] [Abstract][Full Text] [Related]
3. Natural and synthetic inhibitors of the tumor-associated serine protease urokinase-type plasminogen activator.
Magdolen V; Arroyo de Prada N; Sperl S; Muehlenweg B; Luther T; Wilhelm OG; Magdolen U; Graeff H; Reuning U; Schmitt M
Adv Exp Med Biol; 2000; 477():331-41. PubMed ID: 10849761
[No Abstract] [Full Text] [Related]
4. Identification of orally bioavailable, non-amidine inhibitors of Urokinase Plasminogen Activator (uPA).
West CW; Adler M; Arnaiz D; Chen D; Chu K; Gualtieri G; Ho E; Huwe C; Light D; Phillips G; Pulk R; Sukovich D; Whitlow M; Yuan S; Bryant J
Bioorg Med Chem Lett; 2009 Oct; 19(19):5712-5. PubMed ID: 19703768
[TBL] [Abstract][Full Text] [Related]
5. Crystals of urokinase type plasminogen activator complexes reveal the binding mode of peptidomimetic inhibitors.
Zeslawska E; Jacob U; Schweinitz A; Coombs G; Bode W; Madison E
J Mol Biol; 2003 Apr; 328(1):109-18. PubMed ID: 12684001
[TBL] [Abstract][Full Text] [Related]
6. Engineering inhibitors highly selective for the S1 sites of Ser190 trypsin-like serine protease drug targets.
Katz BA; Sprengeler PA; Luong C; Verner E; Elrod K; Kirtley M; Janc J; Spencer JR; Breitenbucher JG; Hui H; McGee D; Allen D; Martelli A; Mackman RL
Chem Biol; 2001 Nov; 8(11):1107-21. PubMed ID: 11731301
[TBL] [Abstract][Full Text] [Related]
7. Discovery of selective urokinase plasminogen activator (uPA) inhibitors as a potential treatment for multiple sclerosis.
Islam I; Yuan S; West CW; Adler M; Bothe U; Bryant J; Chang Z; Chu K; Emayan K; Gualtieri G; Ho E; Light D; Mallari C; Morser J; Phillips G; Schaefer C; Sukovich D; Whitlow M; Chen D; Buckman BO
Bioorg Med Chem Lett; 2018 Nov; 28(20):3372-3375. PubMed ID: 30201291
[TBL] [Abstract][Full Text] [Related]
8. Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride.
Jankun J; Skrzypczak-Jankun E
Cancer Biochem Biophys; 1999 Jul; 17(1-2):109-23. PubMed ID: 10738907
[TBL] [Abstract][Full Text] [Related]
9. Design of novel and selective inhibitors of urokinase-type plasminogen activator with improved pharmacokinetic properties for use as antimetastatic agents.
Schweinitz A; Steinmetzer T; Banke IJ; Arlt MJ; Stürzebecher A; Schuster O; Geissler A; Giersiefen H; Zeslawska E; Jacob U; Krüger A; Stürzebecher J
J Biol Chem; 2004 Aug; 279(32):33613-22. PubMed ID: 15150279
[TBL] [Abstract][Full Text] [Related]
10. Amido-(propyl and allyl)-hydroxybenzamidines: development of achiral inhibitors of factor Xa.
Gong Y; Pauls HW; Spada AP; Czekaj M; Liang G; Chu V; Colussi DJ; Brown KD; Gao J
Bioorg Med Chem Lett; 2000 Feb; 10(3):217-21. PubMed ID: 10698439
[TBL] [Abstract][Full Text] [Related]
11. Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 3: 1-isoquinolinylguanidines.
Barber CG; Dickinson RP; Fish PV
Bioorg Med Chem Lett; 2004 Jun; 14(12):3227-30. PubMed ID: 15149680
[TBL] [Abstract][Full Text] [Related]
12. 3-Amidinophenylalanine-based inhibitors of urokinase.
Stürzebecher J; Vieweg H; Steinmetzer T; Schweinitz A; Stubbs MT; Renatus M; Wikström P
Bioorg Med Chem Lett; 1999 Nov; 9(21):3147-52. PubMed ID: 10560742
[TBL] [Abstract][Full Text] [Related]
13. Design of benzamidine-type inhibitors of factor Xa.
Gabriel B; Stubbs MT; Bergner A; Hauptmann J; Bode W; Stürzebecher J; Moroder L
J Med Chem; 1998 Oct; 41(22):4240-50. PubMed ID: 9784099
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological activity of novel rigid amidino-phenylalanine derivatives as inhibitors of thrombin.
Mack H; Pfeiffer T; Hornberger W; Böhm HJ; Höffken HW
J Enzyme Inhib; 1995; 9(1):73-86. PubMed ID: 8568568
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and SAR of benzamidine factor Xa inhibitors containing a vicinally-substituted heterocyclic core.
Fevig JM; Pinto DJ; Han Q; Quan ML; Pruitt JR; Jacobson IC; Galemmo RA; Wang S; Orwat MJ; Bostrom LL; Knabb RM; Wong PC; Lam PYS ; Wexler RR
Bioorg Med Chem Lett; 2001 Mar; 11(5):641-5. PubMed ID: 11266160
[TBL] [Abstract][Full Text] [Related]
16. Crystals of the urokinase type plasminogen activator variant beta(c)-uPAin complex with small molecule inhibitors open the way towards structure-based drug design.
Zeslawska E; Schweinitz A; Karcher A; Sondermann P; Sperl S; Stürzebecher J; Jacob U
J Mol Biol; 2000 Aug; 301(2):465-75. PubMed ID: 10926521
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and SAR of monobenzamidines and aminoisoquinolines as factor Xa inhibitors.
Zhang P; Zuckett JF; Woolfrey J; Tran K; Huang B; Wong P; Sinha U; Park G; Reed A; Malinowski J; Hollenbach S; Scarborough RM; Zhu BY
Bioorg Med Chem Lett; 2002 Jun; 12(12):1657-61. PubMed ID: 12039584
[TBL] [Abstract][Full Text] [Related]
18. Angiostatic activity of synthetic inhibitors of urokinase type plasminogen activator.
Swiercz R; Skrzypczak-Jankun E; Merrell MM; Selman SH; Jankun J
Oncol Rep; 1999; 6(3):523-6. PubMed ID: 10203585
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of 4,5-disubstituted-thiophene-2-amidines as potent urokinase inhibitors.
Rudolph MJ; Illig CR; Subasinghe NL; Wilson KJ; Hoffman JB; Randle T; Green D; Molloy CJ; Soll RM; Lewandowski F; Zhang M; Bone R; Spurlino JC; Deckman IC; Manthey C; Sharp C; Maguire D; Grasberger BL; DesJarlais RL; Zhou Z
Bioorg Med Chem Lett; 2002 Feb; 12(3):491-5. PubMed ID: 11814826
[TBL] [Abstract][Full Text] [Related]
20. Elaborate manifold of short hydrogen bond arrays mediating binding of active site-directed serine protease inhibitors.
Katz BA; Elrod K; Verner E; Mackman RL; Luong C; Shrader WD; Sendzik M; Spencer JR; Sprengeler PA; Kolesnikov A; Tai VW; Hui HC; Breitenbucher JG; Allen D; Janc JW
J Mol Biol; 2003 May; 329(1):93-120. PubMed ID: 12742021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
